Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...

The "GLP Laboratory Compliance Documentation and Recordkeeping" training has been added to ResearchAndMarkets.com's offering.

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

Telomir Pharmaceuticals (TELO) announced results from a comprehensive series of IND-enabling Good Laboratory Practice toxicology and safety ...